Full Press Release Details
MINNEAPOLIS , Feb. 2, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH ) today reported its financial results for the second quarter ended December 31, 2020 .
Second Quarter FY2021 Snapshot
The Company's financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). Adjusted EPS, adjusted earnings, adjusted gross margin, adjusted operating income, organic growth, and adjusted operating margin are non-GAAP measures that exclude certain items detailed later in this press release under the heading "Use of non-GAAP Adjusted Financial Measures." A reconciliation of GAAP to non-GAAP financial measures is included in this press release.
"I would like to thank the entire global Bio-Techne team for delivering such a stellar quarter," said Chuck Kummeth , President and Chief Executive Officer of Bio-Techne. "To achieve 19% organic growth, with only 3% attributed to Covid tailwinds, attests to the strong execution of our strategy we have implemented in recent years. It's great to see this planning succeed in virtually all areas of our business. We delivered this organic growth with a continued focus on profitability, as our adjusted operating margin improved over 500 basis points year over year to 38.7%."
Kummeth added, "The continued ramp of our high-growth platforms including Exosome Dx, Cell and Gene Therapy, GMP Proteins, proteomics instrumentation and genomics will be exciting to watch as we strive for continued double-digit organic growth. Our expanded digital platform, increased global brand presence, and world class customer relationships has brought our renowned protein and antibody products (as well as our new platforms) to the forefront of the life science tools and diagnostics industry."
Second Quarter Fiscal 2021
Net sales for the second quarter increased 21% to $224.3 million . Organic growth was 19% compared to the prior year, with foreign currency exchange having a favorable impact of 2% and acquisitions contributing an immaterial amount to revenue growth.
GAAP Earnings Results
GAAP EPS decreased to $1.15 per diluted share, versus $3.02 in the same quarter last year. GAAP EPS was favorably impacted by a non-recurring gain of approximately $121 million on our ChemoCentryx investment in the second quarter of fiscal 2020. GAAP operating income for the second quarter of fiscal 2021 increased 37.9% to $51.0 million , compared to $37.0 million in the second quarter of fiscal 2020. GAAP operating margin was 22.7%, compared to 20.0% in the second quarter of fiscal 2020. GAAP operating margin compared to prior year was positively impacted by volume leverage and cost management.
Non-GAAP Earnings Results
Adjusted EPS increased to $1.62 per diluted share, versus $1.08 in the same quarter last year, an increase of 50%. Adjusted EPS increased due to revenue growth and operating margin expansion. Adjusted operating income for the second quarter of fiscal 2021 increased 40% compared to the second quarter of fiscal 2020. Adjusted operating margin was 38.7%, compared to 33.4% in the second quarter of fiscal 2020. Adjusted operating margin compared to the prior year was favorably impacted by volume leverage and cost management.
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.
Protein Sciences Segment
The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment's second quarter fiscal 2021 net sales were $172.2 million , an increase of 22% from $141.5 million for the second quarter of fiscal 2020. Organic growth for the segment was 19%, with foreign currency exchange having a favorable impact of 3% on revenue growth and acquisitions contributing an immaterial amount to revenue growth. Protein Sciences segment's operating margin was 46.6% in the second quarter of fiscal 2021 compared to 43.0% in the second quarter of fiscal 2020. The segment's operating margin compared to the prior year was positively impacted by volume leverage and cost management.
Diagnostics and Genomics Segment
The Company's Diagnostics and Genomics segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Genomics segment also develops and provides in situ hybridization products as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Genomics segment's second quarter fiscal 2021 net sales were $52.5 million , an increase of 20% from $43.8 million for the second quarter of fiscal 2020. Organic growth for the segment was 19% with foreign currency exchange having a 1% impact on revenue. The Diagnostics and Genomics segment's operating margin was 15.5% in the second quarter of fiscal 2021 compared to 2.2% in the second quarter of fiscal 2020. The segment's operating margin was favorably impacted by volume leverage and cost management.
Conference Call
Bio-Techne will host an earnings conference call today, February 2, 2021 at 8:00 a.m. CST . To listen, please dial 1-877-407-9208 or 1-201-493-6784 for international callers, and reference conference ID 13715028. The earnings call can also be accessed via webcast through the following link http://public.viavid.com/index.php?id=143031 .
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13715028. The replay will be available from 11:00 a.m. CST on Tuesday, February 2, 2021 until 11:00 p.m. CST on Tuesday , March 2, 2021.
Use of non-GAAP Adjusted Financial Measures:
This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:
Our non-GAAP financial measure of organic growth represents revenue growth excluding revenue from acquisitions within the preceding 12 months as well as the impact of foreign currency. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period.
Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including non-recurring costs and gains. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of the changes in fair value contingent consideration, and other non-recurring items including gains or losses on legal settlements and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Additionally, these amounts can vary significantly from period to period based on current activity.
Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, customer site closures or supply chain issues resulting from the COVID-19 pandemic, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Bio-Techne Corporation (NASDAQ: TECH ) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and has over 2,300 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com .
| Contact: | David Clair, Senior Director, Investor Relations & Corporate Development |
| [email protected] | |
| 612-656-4416 |
| BIO-TECHNE CORPORATION CONSOLIDATED STATEMENTS OF EARNINGS (In thousands, except per share data) (Unaudited) | ||||||||||||||||
| QUARTER ENDED | SIX MONTHS ENDED | |||||||||||||||
| 12/31/20 | 12/31/19 | 12/31/20 | 12/31/19 | |||||||||||||
| Net sales | $ | 224,253 | $ | 184,934 | $ | 428,452 | $ | 368,177 | ||||||||
| Cost of sales | 73,353 | 63,531 | 139,821 | 128,361 | ||||||||||||
| Gross margin | 150,900 | 121,403 | 288,631 | 239,816 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Selling, general and administrative | 83,116 | 68,030 | 155,714 | 137,040 | ||||||||||||
| Research and development | 16,789 | 16,381 | 32,830 | 32,459 | ||||||||||||
| Total operating expenses | 99,905 | 84,411 | 188,544 | 169,499 | ||||||||||||
| Operating income | 50,995 | 36,992 | 100,087 | 70,317 | ||||||||||||
| Other income (expense) | 5,373 | 113,334 | (4,381) | 97,812 | ||||||||||||
| Earnings before income taxes | 56,368 | 150,326 | 95,706 | 168,129 | ||||||||||||
| Income taxes | 10,224 | 30,704 | 16,168 | 34,111 | ||||||||||||
| Net earnings, including noncontrolling interest | $ | 46,144 | $ | 119,622 | $ | 79,538 | $ | 134,018 | ||||||||
| Net earnings attributable to noncontrolling interest | (130) | - | (130) | - | ||||||||||||
| Net earnings attributable to Bio-Techne | 46,274 | 119,622 | 79,668 | 134,018 | ||||||||||||
| Earnings per share: | ||||||||||||||||
| Basic | $ | 1.20 | $ | 3.13 | $ | 2.06 | $ | 3.51 | ||||||||
| Diluted | $ | 1.15 | $ | 3.02 | $ | 1.98 | $ | 3.40 | ||||||||
| Weighted average common shares outstanding: | ||||||||||||||||
| Basic | 38,691 | 38,167 | 38,614 | 38,100 | ||||||||||||
| Diluted | 40,257 | 39,550 | 40,135 | 39,370 |
| BIO-TECHNE CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (In thousands) (Unaudited) | ||||||||
| ASSETS | 12/31/20 | 6/30/20 | ||||||
| Cash and equivalents | $ | 165,526 | $ | 146,625 | ||||
| Short-term available-for-sale investments | 117,426 | 124,268 | ||||||
| Accounts receivable, net | 128,243 | 122,534 | ||||||
| Inventories | 106,590 | 103,152 | ||||||
| Other current assets | 24,148 | 24,341 | ||||||
| Total current assets | 541,933 | 520,920 | ||||||
| Property and equipment, net | 195,602 | 176,829 | ||||||
| Right of use asset | 68,154 | 71,465 | ||||||
| Goodwill and intangible assets, net | 1,250,838 | 1,244,853 | ||||||
| Other assets | 11,339 | 13,522 | ||||||
| Total assets | $ | 2,067,866 | $ | 2,027,589 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Accounts payable and accrued expenses | $ | 70,132 | $ | 63,270 | ||||
| Contract liabilities | 13,217 | 13,049 | ||||||
| Income taxes payable | 3,658 | 2,376 | ||||||
| Contingent consideration payable | 4,983 | 5,938 | ||||||
| Operating lease liabilities – current | 9,912 | 9,535 | ||||||
| Current portion of long-term debt obligations | 12,500 | 12,500 | ||||||
| Other current liabilities | 3,166 | - | ||||||
| Total current liabilities | 117,568 | 106,668 | ||||||
| Deferred income taxes | 105,342 | 101,090 | ||||||
| Long-term debt obligations | 219,035 | 344,243 | ||||||
| Operating lease liabilities | 63,672 | 67,248 | ||||||
| Long-term contingent consideration payable | 5,599 | 199 | ||||||
| Other long-term liabilities | 25,796 | 26,949 | ||||||
| Stockholders' equity | 1,530,854 | 1,381,192 | ||||||
| Total liabilities and stockholders' equity | $ | 2,067,866 | $ | 2,027,589 |
| BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE (Unaudited) | ||||||||||||||||
| QUARTER ENDED | SIX MONTHS ENDED | |||||||||||||||
| 12/31/20 | 12/31/19 | 12/31/20 | 12/31/19 | |||||||||||||
| Gross margin percentage – GAAP | 67.3 | % | 65.6 | % | 67.4 | % | 65.1 | % | ||||||||
| Identified adjustments: | ||||||||||||||||
| Costs recognized upon sale of acquired inventory | - | - | % | - | - | % | ||||||||||
| Amortization of intangibles | 3.9 | % | 4.7 | % | 4.0 | % | 4.7 | % | ||||||||
| Stock compensation expense - COGS | 0.3 | % | 0.3 | 0.3 | % | 0.2 | ||||||||||
| Gross margin percentage - Adjusted | 71.5 | % | 70.6 | % | 71.7 | % | 70.0 | % |
| BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE (Unaudited) | ||||||||||||||||
| QUARTER ENDED | SIX MONTHS ENDED | |||||||||||||||
| 12/31/20 | 12/31/19 | 12/31/20 | 12/31/19 | |||||||||||||
| Operating margin percentage – GAAP | 22.7 | % | 20.0 | % | 23.4 | % | 19.1 | % | ||||||||
| Identified adjustments: | ||||||||||||||||
| Costs recognized upon sale of acquired inventory | - | - | % | - | - | % | ||||||||||
| Amortization of intangibles | 6.8 | % | 8.2 | % | 7.1 | % | 8.2 | % | ||||||||
| Acquisition related expenses | 2.0 | % | -0.5 | % | 1.1 | % | 0.1 | % | ||||||||
| Stock-based compensation | 7.2 | % | 5.7 | % | 6.9 | % | 5.3 | % | ||||||||
| Operating margin percentage - Adjusted | 38.7 | % | 33.4 | % | 38.5 | % | 32.7 | % |
| BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED NET EARNINGS and EARNINGS per SHARE (In thousands, except per share data) (Unaudited) | ||||||||||||||||
| QUARTER ENDED | SIX MONTHS ENDED | |||||||||||||||
| 12/31/20 | 12/31/19 | 12/31/20 | 12/31/19 | |||||||||||||
| Net earnings – GAAP attributable to Bio-Techne | $ | 46,274 | $ | 119,622 | $ | 79,668 | $ | 134,018 | ||||||||
| Identified adjustments attributable to Bio-Techne: | ||||||||||||||||
| Costs recognized upon sale of acquired inventory | 11 | - | 11 | - | ||||||||||||
| Amortization of intangibles | 14,994 | 15,108 | 30,495 | 30,008 | ||||||||||||
| Acquisition related expenses | 4,514 | (787) | 4,746 | 617 | ||||||||||||
| Stock-based compensation | 16,225 | 10,618 | 29,558 | 19,418 | ||||||||||||
| Restructuring costs | 142 | - | 142 | - | ||||||||||||
| Realized and unrealized loss (gain) on investments and Other | (10,197) | (120,449) | (5,846) | (110,048) | ||||||||||||
| Tax impact of above adjustments | (3,041) | 24,132 | (7,936) | 17,151 | ||||||||||||
| Tax impact of discrete items | (3,674) | (5,384) | (7,826) | (6,655) | ||||||||||||
| Net earnings - Adjusted | $ | 65,248 | $ | 42,860 | $ | 123,012 | $ | 84,510 | ||||||||
| Earnings per share - diluted – Adjusted | $ | 1.62 | $ | 1.08 | $ | 3.06 | $ | 2.15 |
| BIO-TECHNE CORPORATION SEGMENT REVENUE (In thousands) (Unaudited) | ||||||||||||||||
| QUARTER ENDED | SIX MONTHS ENDED | |||||||||||||||
| 12/31/20 | 12/31/19 | 12/31/20 | 12/31/19 | |||||||||||||
| Protein Sciences segment revenue | $ | 172,179 | $ | 141,517 | $ | 326,625 | $ | 282,512 | ||||||||
| Diagnostics and Genomics segment revenue | 52,469 | 43,846 | 102,595 | 86,397 | ||||||||||||
| Intersegment revenue | (395) | (429) | (768) | (732) | ||||||||||||
| Consolidated revenue | $ | 224,253 | $ | 184,934 | $ | 428,452 | $ | 368,177 |
| BIO-TECHNE CORPORATION SEGMENT OPERATING INCOME (In thousands) (Unaudited) | ||||||||||||||||
| QUARTER ENDED | SIX MONTHS ENDED | |||||||||||||||
| 12/31/20 | 12/31/19 | 12/31/20 | 12/31/19 | |||||||||||||
| Protein Sciences segment operating income | $ | 80,246 | $ | 60,872 | $ | 150,598 | $ | 120,410 | ||||||||
| Diagnostics and Genomics segment operating income | 8,107 | 975 | 16,781 | 1,875 | ||||||||||||
| Segment operating income | 88,353 | 61,847 | 167,379 | 122,285 | ||||||||||||
| Corporate general, selling, and administrative | (1,520) | (12) | (2,482) | (2,113) | ||||||||||||
| Adjusted operating income | 86,833 | 61,835 | 164,897 | 120,172 | ||||||||||||
| Cost recognized upon sale of acquired inventory | (23) | - | (23) | - | ||||||||||||
| Amortization of intangibles | (15,027) | (15,108) | (30,528) | (30,008) | ||||||||||||
| Acquisition related expenses | (4,421) | 881 | (4,558) | (429) | ||||||||||||
| Stock-based compensation | (16,225) | (10,618) | (29,557) | (19,418) | ||||||||||||
| Restructure costs | (142) | - | (142) | - | ||||||||||||
| Operating income | $ | 50,995 | $ | 36,990 | $ | 100,087 | $ | 70,317 |
SOURCE Bio-Techne Corporation